Table 2.
Recurrence-free survival estimates by the risk group in all patients and in patients with hormone receptor (HR)-positive tumors
| N | Number of events | 3-year estimate | 95% confidence interval | P-value | |
|---|---|---|---|---|---|
| Training sets | |||||
| All patients | |||||
| All | 99 | 40 | 58.6 | 48.9–70.3 | |
| High risk clustering | 40 | 23 | 45.1 | 31.7–64.3 | |
| Low risk clustering | 59 | 17 | 66.8 | 54.1–82.5 | 0.002 |
| HR positive | |||||
| All | 53 | 11 | 82.1 | 72.2–93.5 | |
| High risk clustering | 6 | 5 | 16.7 | 2.78–99.7 | |
| Low risk clustering | 47 | 6 | 90.8 | 82.5–99.8 | <0.001 |
| Validation data | |||||
| All patients | |||||
| All | 79 | 37 | 51.8 | 41.6–64.4 | |
| High risk clustering | 21 | 13 | 38.1 | 22.1–65.7 | |
| Low risk clustering | 54 | 24 | 56.7 | 44.9–71.5 | 0.055 |
| HR positive | |||||
| All | 42 | 15 | 70.2 | 57.4–86 | |
| High risk clustering | 5 | 3 | 30 | 6.3–99.9 | |
| Low risk clustering | 37 | 12 | 75 | 62–90.65 | 0.038 |